Experiments on Apo-A2 transgenic rabbits and clinical studies involving patients with coronary artery disease, atherosclerosis, or hypercholesterolemia have shown that increased serum concentration of Apo-A2 may constitute an important contributor to the development of MetS [31,32,33]. This evidence concerns the gene APOA2 and familial hypercholesterolemia.